Intelligent Solutions for Oral Drug DeliveryTM

Welcome to Enteris BioPharma, the oral drug delivery partner of choice for the formulation of BCS Class II, Class III, and Class IV compounds, including peptides.

The pharmaceutical community has long sought more effective ways to increase physician acceptance and patient compliance for medications in a variety of therapeutic indications. Enteris BioPharma has emerged as a leader in innovative oral dosage formulations with our proprietary, cutting-edge oral drug delivery technology.

The Enteris BioPharma simple, elegant, and scalable oral drug delivery solution has overcome previously unmet challenges in both permeability and solubility, with a demonstrated track record of clinical success across a range of compounds. We are dedicated to building long-term, strategic relationships and offer our partners a robust formulation strategy that begins with in-vitro characterization of their compound and goes through optimizing tablet formulations that provide fully optimized GMP clinical trial material.

Learn more about our oral delivery technology here.


    • “We are committed to delivering innovative medicines to meet unmet medical needs. Using our patented delivery technology, we are reformulating injectable molecules into novel oral products that will have significant medical and commercial impact.”
      Joel Tune
      Chief Executive Officer

      “We are focused on solving challenging formulation issues for our partners using our proprietary, cutting edge, delivery technology. Our combined strengths in formulation development and manufacturing uniquely position us to be an industry leader in overcoming the formulation challenges to deliver peptides and small molecules orally.”
      Brian Zietsman
      President and Chief Financial Officer

      “We are dedicated to providing our partners a turnkey solution that enables them to rapidly evaluate and implement our delivery technology in a robust pharmaceutical development strategy. With our proven capabilities, we are able to deliver a full 3.2.P filing package and Clinical Trial Material to allow partners quick entry into clinical evaluation.”
      Paul Shields, Ph.D.
      Chief Operating Officer